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Abstract 
Hepatocellular carcinoma (HCC) is a highly malignant tumor that is prevalent in 
Southeast Asia, including Hong Kong, and sub-Saharan Africa. Surgical resection 
represents the only hope of long-term survival for patients with HCC. However, by 
the time of clinical presentation, more than 80% of the patients are at a late inoperable 
disease stage. This in turn renders systemic chemotherapy as a major treatment option 
for the overall survival improvements. Doxorubicin (DX) and analogues are widely 
used first-line chemotherapeutic agents. Treatment with DX has been shown to 
prolong p atient survival with improvement in disease related symptoms. However, 
the clinical behavior of HCC patients in response to DX can be variable. This is 
largely attributed to the development of tumor drug resistance either at the onset or 
during the course of treatment. Whilst genome-wide molecular investigations on 
HCC by allelotyping and comparative genomic hybridization analyses have indicated 
areas of recurring genetic alterations, correlative studies on the genetic changes with 
drug resistance phenotype have not been described. 
The goal of our study is to enhance our understanding on the genomic and molecular 
changes that confer intrinsic cellular chemo-resistance to DX in HCCs. The DX 
resistance behavior in a panel of 9 HCC cell lines with differing r esistance to DX 
were examined in this study (HepG2, Hep3B，PLC/PRF/5, and six in-house 
established, HKCI-1, 2，3，4，CI and C2). The karyotypic abnormalities were 
examined by Spectral Karyotyping (SKY) and the chromosome loci defined were 
viii 
investigated for underlying deregulated genes by positional expression profiling. 
Quantitative RT-PCR was employed to verify the profiling findings, and was also 
used to examine a number of drug resistance related candidate genes {MDRl, MRPl, 
MGMT, PTEN, BCL2, BAX, TP53 and P21). 
Our results indicated that the cytotoxic effect of DX in cell lines exhibited IC50 
values that ranged from sensitive to resistance (0.07|aM to 3.55^M). While the overall 
chromosome aneuploidy did not correlate with DX resistance, frequent 
rearrangements on chromosome 10 demonstrated significant correlation with 
increasing IC50s (P=0.007). Positional profiling further suggested the consistent 
down-regulation of CG/-18 (CGI-18 protein) and ECHSJ (mitochondrial enoyl-CoA 
hydratase - short chain 1) on chromosome lOq. The array findings were substantiated 
by quantitative RT-PCR, which further pinpointed to a repressed ECHSl expression 
in correlation with DX resistance (P二0.021). Among the candidate drug resistant 
genes studied, an inverse relationship between DX resistance and a reduced P21 
(P=0.034) and 5^Y(P=0.00 2) expression was indicated. 
In summary, by examining karyotypic and molecular abnormalities in HCC cell lines 
with differing resistance to doxorubicin, our study describes the novel finding of 
ECHSl gene down regulation in the doxorubicin chemo-resistance of HCC. The 
present study also highlights the usefulness of multimodality approaches (namely 
SKY, cDNA microarray and quantitative RT-PCR) in identifying genetic markers 











genomic hybridization, CGH )技術進行的肝癌全基因組範圍内的分子研究已經揭 
示出若干多發的遺傳學改變，似是與藥物耐受相關的遺傳學改變還未見報道。 
本研究的目的在於提高對肝癌中與DX原發性細胞耐受相關的基因組以及分了 
改變的認識。在本研究中，我們對 9 種具有不同 D X 反應性的肝癌細胞系 
(HepG2, Hep3B,PLC/PRF/5,以及本實驗室自行建立起來的6種細胞系HKCI-1, 
2, 3, 4，C1和C2)的耐受行爲進行了研究。首先應用光譜核型分析（Spec t ra l 
Karyotyping, S K Y )技術檢測染體核型的異常。之後應用 c D N A微矩陣技術 
(cDNA microarray)在所確定的染色體位點找出潜在的表達水平降低的基因。再 
應用定量逆轉錄聚合酶鏈式反應(RT-PCR)技術驗證cDNA微矩陣資料，同時此 
技術也用於檢測一些藥物耐受相關的候選基因的表達水平 ( M D R 1 , MRP1, 
V 
MGMT\ PTEN, BCL2’ BAX, TP53 以及 P2r)o 
我們的研究結果表明，DX對於不同細胞系的細胞毒效果差別很大，表現在半 
数抑制劑量（ IC50)廣泛分佈於敏感與耐受之間（0 .07M到3 .55M)�雖然總的 
染數目的異常與D X耐受現象沒有明顯的相關性’但 1 0號染色體重組頻率 
卻隨著IC50值的增高而明顯增高（P二0.007)�微矩陣資料進一步顯示位於10號 
染 f t體上的兩個基因CG/- /<5(CGI-18蛋白）以及五0/57(線粒體乙醜輔酶A水 
合醜-短鏈1)表達水平的一致降低。RT-PCR技術驗證的微矩陣技術的結果表 
明ECHS1基因表達水平的降低與DX耐受程度明顯相關 (P=0.021)�在所研究的 







Table of contents 
Acknowledgements i 
Abstract (in English) “ 
Abstract (in Chinese) iv 
Table of contents vi 
List of figures x 
List of tables 
Abbreviations 
CHAPTER ONE: INTRODUCATION 1 
1.1 Hepatocellular Carcinoma 2 
1.1.1. Epidemiology ofHCC 2 
1.1.2. The major risk factors 2 
1.1.3. Management of HCC 3 
1.2 Mechanisms of multidrug resistance (MDR) in cancer cells 4 
1.2.1. Major mechanisms in reduced drug accumulation 5 
1.2.1.1. P-glycoprotein (P-gp) 6 
1.2.1.2. Multidrug Resistance-associated Protein (MRP) 7 
1.2.1.3. Other effluxes 8 
1.2.2. Inhibition of apoptotic signaling pathways 11 
1.2.2.1. TP53 and multidrug resistance 11 
1.2.2.2. Anti-oncogene PTEN and drug resistance 13 
viii 
1.2.2.3. Influence of BCL2 family on drug resistance 14 
1.3 The chemotherapeutic agent of doxorubicin 15 
1.4 Aims of study 18 
CHAPTER 2 MATERIALS AND METHODS 20 
2.1 Cell culture 21 
2.1.1 Cell lines and cell culture 21 
2.1.2 Subculture 23 
2.1.3 Cryopreservation 23 
2.1.4 Recovery of cryopreserved culture 24 
2.1.5 Cell number counting 24 
2.2 MTT experiments 26 
2.2.1 Determination of cell seeding density 26 
2.2.2 Cytotoxic assay 27 
2.3 Spectral Karytyping (SKY) 27 
2.3.1 Pretreatment of chromosome slides for SKY 28 
2.3.2 Hybridization 28 
2.3.3 Detection 29 
2.4 Positional expression profiling 30 
2.4.1 RNA extraction 32 
2.4.2 Reverse transcription and cDNA labling 34 
2.4.3 Probe purification and hybridization 34 
2.4.4 Image acquisition and data analysis 35 
viii 
2. 5 Quantitative RT-PCR 37 
2.5.1 RNA extraction 37 
2.5.2 Primer design 37 
2.5.3 Reverse transcription 37 
2.5.4 Quantitative PGR 39 
2.6. Statistical analysis 40 
CHAPTER 3 RESULTS 43 
Introduction 44 
3.1 Doxorubicin resistance in HCC cell lines 44 
3.2 Candidate drug resistance genes 56 
3.3 The roles of chromosomal instability 58 
3.4 Candidate resistance genes identified in chromosome 10 69 
CHAPTER 4 DISCUSSION 75 
Introduction 76 
4.1 In vitro cell models facilitate drug resistance investigations 77 
4.2 Aneuploidy and DX resistance 78 
4.3 The role of known resistance genes on chromosome 10 79 
4.4 Identification of novel DX resistance genes on chromosome 10 80 
4.5 Common drug resistance genes 83 
4.5. l.The roles of classical drug resistance 85 
4.5.2. Inhibition of apoptosis and deregulation of cell cycle 86 
viii 
CHAPTER 5 PROPOSED FUTURE STUDIES 90 
5.1. Validate significant in vitro findings by clinical trials 91 
5.2. Molecular mechanisms in inactivation ofECHSl in resistant cells 92 




List of Figures 
Figure 1.1. Membrane topology model of two main MDR transporters 10 
Figure 1.2. Structure formula of doxorubicin 17 
Figure 2.1 Hemacytometer counting chamber 25 
Figure 2.2 The basic principle of microarray 31 
Figure 2.3. RNA extraction from HCC cell lines 33 
Figure 2.4. Melting curve of real time RT-PCR for sample genes 41-42 
Figure 3.1. Seeding density determined by MTT 46-49 
Figure 3.2. The IC50 values for HCC cell lines 50 
Figure 3.3. Growth kinetics of HCC cell lines treated with doxorubicin 52-55 
Figure 3.4. SKY analysis on HKCI-3 67 
Figure 3.5. SKY analysis on Hep3B 68 
Figure 3.6. Gene expression profiling by cDNA microarray 71-72 
Figure 3.7. Expression levels of candidate 73 
viii 
List of Tables 
Table 2.1. Characterization of ATCC cell lines 22 
Table 2.2. Clinicopathologic characterization of patients 22 
Table 2.3. Primers used for quantitative RT - PGR 38 
Table 3.1. The IC50 values of DX on HCC Cell lines 51 
Table 3.2. Correlation between IC50 and expression levels of candidate 
drug resistant gene 57 
Table 3.3. SKY analysis on HCC cell lines 59-63 
Table 3.4. Correlation between IC50 and chromosome instability in HCC 
cell lines 64-66 
Table 3.5. Correlation between IC50 and expression levels of candidate 
genes in chromosome 10 74 
Table 4.1. Summary of data correlating drug resistance related genes 
in HCC cells 84 
viii 
Abbreviations 
Hepatocellular carcinoma HCC 
Multidrug resistance MDR 
ATP Binding Cassette superfamily ABC 
Doxorubicin DX 
4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide MTT 
Inhibitory concentration 50% IC50 
Micro mole I^ M 
Base pair bp 
4,6 diamino-2-phenylindole DAPI 
Spectral Karytyping SKY 
Multidrug resistance Protein 1 MDRl 
P-glycoprotein P_gP 
Multidrug Resistance-associated Protein 1 MRPl 
B cell Lymphoma-2 BCL2 
Bcl-2-associated X protein BAX 
Phosphates and tensin homolog (mutated in multiple 
advanced cancers 1) PTEN 
0-6-methylguanine-DNA methyltransferase MGMT 
Mitochondrial enoyl-CoA hydratase - short chain 1 ECHSl 
CGI-18 protein CGI-18 






1.1. Hepatocellular carcinoma 
1.1.1. Epidemiology of HCC 
Hepatocellular carcinoma (HCC) is the 5th most common malignancy worldwide, 
which alone accounts for approximately half a million deaths annually (Bosch et a l , 
1999; Pisani et al., 1999，Hashem et al., 2003). It is well known that the incidence of 
HCC various considerably with geographical regions. Of the approximate 530,000 
new cases of HCC diagnosed each year, more than 85% occur in areas of Southeast 
Asia, including China and sub-Saharan Africa (Mozambique and South Africa) 
(Monto et al., 2001). Although the frequency of HCC in North America and Western 
Europe is much lower, recent data has shown a rising incidence in these areas (Di 
Bisceglie et al., 1998; Schafer et al., 1999; Yu et a l , 2000). 
HCC is a rapidly fatal malignancy with the incidence-to-mortality ratio approaching 1 
(Bosch et al., 1999). The data on HCC mortality in 28 countries worldwide indicated 
that HCC mortality in males was highest in Hong Kong. Moreover, irrespective to 
geographic location, HCC affects males more than females (Cancer incidence and 
mortality in Hong Kong - 1998-1999). 
1.1.2. The major risk factors 
HCC is well recognized as being part of the natural history of liver cirrhosis (Oka et 
al., 1990; Colombo et al., 1991; Llovet et al., 2003; Velazquez et al., 2003). Although 
cirrhosis of any underlying cause increases the risk of developing HCC, cirrhosis 
associated with chronic HBV and HCV infection or hemochromatosis carries the 
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greatest risk. Additional factors such as concurrent alcohol (Kubo et al.，1998) or 
dietary aflatoxin exposure (Sun et al , 1999) also contribute to the relative risk of 
developing HCC. 
In Hong Kong, HBV infection is one of the most important etiological factors. 
Studies had shown that some 85.3% - 91.6% of symptomatic HCC cases had 
evidence of HBV infection (Shiu et al., 1990; Lai et al., 1992). Furthermore, 
approximately 1.34% of Hong Kong Chinese patients with chronic HBV infection 
develop HCC over a 5 year period (Lee et al., 1999). 
1.1.3. Management of HCC 
HCC patients have a dismal prognosis. Surgery, in the form of either hepatic 
resection or liver transplantation, is the only potential curative treatment for earlier 
stages HCC (Colleoni et al , 1998; Mor et al., 1998; Bismuth et al., 1999; Lo et al.， 
2002). However, due to the relative paucity of symptoms in the early stages and the 
rapid doubling time of the tumor, most HCCs are discovered in advanced stages 
(Venook et al., 2002). Furthermore, most patients developed recurrence and/or 
metastases even after surgery (Michel et al.,1997; Dmitrewski et al.,1998). Therefore, 
in addition to surgical treatment, it is often necessary to employ other nonsurgical 
treatments. Given the poor tolerance of normal liver tissue to radiation, the 
applicability o f radiation therapy for achieving local control of HCC has therefore 
limited utility. There has been no survival benefit observed with the treatment of 
whole liver radiotherapy. Gene therapy is an exciting approach to treating HCC, but 
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is still largely confined to preclinical and experimental settings (Schmitz et al., 2002). 
Some evidence indicated that patients with inoperable HCC may benefit from local 
ablative therapies, such as ethanol injection, hepatic embolization and radiofrequency 
ablation. A survival benefit with transcatheter arterial chemoembolization (TACE) 
therapy was suggested in a clinical trial conducted in Hong Kong (Lo et al., 2002). 
TACE is known as a targeted therapy that combines the delivery of chemotherapy at 
higher local concentration to tumor cells with minimization of systemic side effects, 
and arterial embolization to induce ischemic necrosis. An ideal patient for TACE has 
adequate 1 iver function, has a s mall HCC c onfined to the 1 iver, and has n o b iliary 
abnormalities or impaired portal flow due to hepatofugal flow or portal vein 
thrombosis (Caturelli et al., 2000). For those patients with advanced HCC, systemic 
chemotherapy has been widely employed. Currently, in addition to improve prospects 
for survival and effective palliation, chemotherapy is increasingly being used in both 
neoadjuvant and postoperative adjuvant settings. However, due to the intrinsic or 
acquired drug resistance phenotype, the efficiency of chemotherapeutic agents in 
HCC remained modest. 
1.2. Mechanisms of multidrug resistance (MDR) in cancer cells 
The resistance of human malignancy to multiple chemotherapeutic agents remains a 
major obstacle in cancer therapy. Drug resistance in cancer is often referred to as 
multidrug resistance (MDR) because when cells are resistant, they often exhibit 
simultaneous resistance to a number of structurally and functionally unrelated 
chemotherapeutic agents. This multidrug resistance (MDR) phenomenon can be 
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intrinsic or acquired, depending on the time of its occurrence, either before (intrinsic) 
or after chemotherapy (acquired), and can lead to a complete ineffectiveness of any 
treatment with dramatic consequences for the patients. 
The MDR phenotype was first found in cell culture experiments in 1970 (Biedler et 
al., 1970). During the last two decades molecular investigations have led to our 
increasing understanding of the mechanisms responsible for the resistance. The 
concept of MDR is based on the hypothesis that MDR is a multifactorial event caused 
by different molecular mechanisms being switched on and off or temporarily being 
activated together. These mechanisms may operate at different steps of the cytotoxic 
action, and range from a decrease of drug accumulation in the cell to the abrogation 
of apoptosis or cell cycle arrest induced by the chemical substance (Ruley et a l , 1996; 
Fojo et al , 2003; Tsuruo et al., 2003). 
1.2.1. Major mechanisms in reduced drug accumulation 
A dominant feature of MDR is a decreased accumulation of cytotoxic drugs in cells. 
Indeed, both electron microscopy and analysis of lipids in the membranes of MDR 
cells revealed differences between drug sensitive and drug resistant cells (Simon et a l , 
1994). Further evidence indicated that this difference generally results from 
overexpression of ATP-dependent cassette (ABC) transporters, which are capable of 
extruding a wide variety of drugs taken up by cells through passive diffusion and, as a 
result, the drug intracellular levels do not reach a toxic concentration (Juliano et al., 
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1976). This mechanism is generally known as the classical multidrug resistance 
(Gottesman et al.，2002). 
1.2.1.1 P-glycoprotein (P-gp) 
The widely studied and best characterized mechanism that is responsible for MDR is 
the overexpression of the MDRl gene product, P-Glycoprotein (P-gp). The P-gp is 
also known as the ABC subfamily Bl, ABCBl (Juranka et al., 1989; Roninson et al , 
1992; Gottesman et al., 1993). It is a 170 kD transmembrane protein that consists of 
twelve hydrophobic transmembrane segments and two ATP-binding domains (Figure 
1.1). It is believed that overexpression of P-gp confers drug resistance to diverse 
antitumor drugs, such as vinblastine, vincristine, doxorubicin, duaunorubicin, 
etoposide, paclitaxel, and many others (Chen et al., 1986). One of most popular 
hypotheses proposes that these drug molecules bind to a specific site of P-gp within 
the lipid bilayer of the cell plasma membrane, and then by means of the energy of 
ATP hydrolysis, the drug molecules are transported out of the cell. Indeed, 
chemotherapeutic drugs were shown to be bound to the membranes of drug resistant 
cells better than by those of sensitive ones. Consequently, these drugs were observed 
to be excluded from drug resistant cells with greater speed (Bradley et al , 1988). 
Further evidence from transfection studies indicated that MDRl gene overexpression 
was sufficient to confer multidrug resistance in cancer cells (Gros et al., 1986). So far, 
many investigators have reported that the expression of P-gp is elevated in 
intrinsically drug resistant cancer cells of the colon, kidney and adrenal as well as in 
some tumors that acquire drug resistance after chemotherapy (Ro et al., 1990; 
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Chevillard et al.，1996; Chung et al., 1997; Trock et al.，1997; Young et al.，1999; 
Chiou et al., 2003). 
1.2.1.2. Multidrug Resistance-associated Protein (MRP) 
Despite modulators of the P-gp activity have been shown to inhibit the drug efflux in 
laboratory models (Thierry et al., 1993； Kakumoto et al., 2003; Arora et a l , 2004) 
and clinical settings (Sonneveld et al , 1992; Sonneveld et al., 1994; Chan et al., 
1996)，the lack of P-gp expression in some multidrug-resistant cells has stimulated 
the search for other efflux pumps. A 190 kD Multidrug Resistance-associated Protein 
1 {MRPl) was discovered in 1992 (Cole et al., 1992). MRP J, like P-gp, belongs to the 
family of ABC transporters (figure 1.1). It also functions as an energy-dependent 
pump excluding toxic substances from the cells, but further work showed that there is 
a preferential transport of glutathione, glucuronate, or sulfate conjugates with MRPl 
(Cole et al., 1994; Muller et al , 1994; Loe et a l , 1998; Hipfner et a l , 1999). On one 
hand, the overall expression levels of MRPl were found to be well correlated with 
drug resistance in a number of cases (Cole et al , 1998). On the other, some studies 
implied that MRPl may be also involved in the intracellular drug redistribution which 
in turn may contribute to the drug resistance phenotype. The evidence comes from the 
transfection studies by Almquist et al. Their results showed that the cells with higher 
percentages of endocytotic distribution of MRPl tended to possess greater drug 
resistance ability (Almquist et al., 1995). Similarly, Liang et al (2003) reported that 
multidrug resistance was accompanied by mislocalization, but not the overexpression 
of MRP J in human KB epidermoid adenocarcinoma (a variant of HeLa) cells. 
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In addition, the second member of the MRP (ABCC) family, MRP2 or canalicular 
multispecific organic anion transporter (cMOAT), is also a transporter of MRP I substrates 
and cisplatin, with the potential of conferring resistance to these agents (Kool et al., 
1997). MRP3 is expressed at high levels in the liver and may be involved in the efflux of 
organic anions from the liver to the blood in the presence of biliary obstruction (Zeng et 
al., 1999). MRP4 and MRP5 have been found to transport nucleoside analogs. Both 
resistant to thiopurines, and MRP4 can also confer resistance to antiretroviral nucleoside 
analogs (Schuetz et al , 1999; Kmh et al, 2001). MRP6 appears to be a lipophilic anion 
pump with a wide spectrum of chemotherapy resistance (Belinsky et al., 2002). 
Nevertheless, the only convincing evidence of a link to clinical drug resistance for the 
MRP family is associated with MRPI (Nakagawa et al., 1997; Tada et al., 2002). The 
potential contributions of other transporters in clinical settings remain to be determined. 
1.2.1.3 Other effluxes 
Many other ABC family members transport drugs in model systems and therefore 
have the potential of causing drug resistance. ABCG2 is known as the mitoxantrone 
resistance gene (MXR), breast cancer resistance protein {BCRP), or ABC transporter 
in placenta (ABC-P). It can present resistance to topotecan and CPT-11 as well as to 
mitoxantrone (Brangi et al., 1999). ABCBIJ, the "sister of P-gp" (SPGP), or the bile 
salt exporter protein (BSEP) has limited resistance to paclitaxel in a laboratory model 
(Childs et al., 1995) ABCA2 is the largest transporter reported to date and has been 
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described in the resistance to estramustine in an ovarian cancer cell line (Vulevic et 
al., 2001). 
Although frequently included in discussions of transporter-mediated resistance 
(Diestra et al., 2003; Rudas et a l , 2003)，lung resistance protein {LRP) is not an ABC 
transporter but is a major vault protein {MVP) (Scheffer et a l , 1995). Without overall 
changes in total cellular drug accumulation, this protein can redistribute drugs from 
nucleus to the cytoplasm and in this way induce resistance to DNA binding drugs 
(Scheffer et al” 1995; List et al., 1996). 
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1.1. Membrane topology model of ABC transporters. 
M D R 1 • • 膽 湖 圓 
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(a) Multidrug resistance protein (MDRl) has 12 transmembrane domains and two 
ATP binding sites, (b) The structures of MRPl is similar in that they possess two 
ATP binding regions. It also contains an additional domain that is composed of five 




1.2.2. Inhibition of apoptotic signaling pathways 
Mechanisms o f c lassical M D R h ave b een e xtensively s tudied i n vitro and in v ivo. 
However, several clinical trials have failed to show any important benefits in 
response to chemotherapy or the length of patient survival using P-gp reversing 
agents. This may be due to the expression or co-expression of other drug resistance 
mechanisms in malignant cells. 
Several studies have shown that most, if not all, chemotherapeutic agents exert their 
anticancer activity by inducing apoptosis; therefore, resistance to apoptosis may be 
one of major factors limiting the effectiveness of anticancer therapy. In the last few 
years, effort has been made to understand the biochemical alterations of cell cycle 
regulation and apoptotic pathways in cancer. Many of these alterations confer a 
multidrug resistant phenotype to malignant cells. 
1.2.2.1. TP53 and multidrug resistance 
The gene TP53 and the genes regulated by TP53 are critical elements of the cell 
response to stress, including cell cycle arrest or apoptosis upon the influence of 
antitumor drugs. However, alterations of TP53 are very frequent in tumors. These 
alterations can therefore be a prior molecular event that can result in the changes of 
tumor cell sensitivity toward drugs, particularly, in MDR (Keshelava et a l , 2001; de 
la Fuente et al., 2003; Blumenthal et a l , 2004; Chan et a l , 2004). 
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Indeed, a large study done on 60 cell lines and more than 100 anticancer drugs by 
National Cancer Institute of the USA revealed a positive correlation between TP53 
status and cell sensitivity to cytotoxic drugs (O'Connor et a l , 1997). Cells with 
mutant TP53 more often were more resistant to various drugs than cells with wild-
type TP53. These data stress the importance of TP53 in the tumor sensitivity to 
chemotherapy. 
However, the issue is far from simple. Studies of TP53 regulation show that the type 
of modifications activating this protein is stress-, tissue-, and species-dependent and 
also depends on the type of amino acid mutation in TP53 (Perego et al., 1997; Glaccia 
et al.,1998). That is to say, different mutations may activate TP53 in different ways, 
which are realized through different signaling pathways being activated (Glaccia et al” 
1998; Yang et al., 2000). For example, TP53 over-expression in human 1 ung cells 
HI299 increased cisplatin cytotoxicity, but protected the cells from the toxic action of 
vepeside (Wang et a l , 1998). 
The proteins of different syntheses are controlled by the transcriptional regulator 
TP53 can also influence cell sensitivity toward drugs. It is known that DNA damage 
activates TP53 and can induce cell cycle arrest by upregulating the expression levels 
of P 2 严“賺 ' . T h e P 2 严 " o v e r e x p r e s s i o n has been shown to enhance the 
chemosensitivity in several cell lines (Kondo et al., 1996; Lincet et al., 2000). In 
contrast, Nefedova et al (2004) found that accumulation o f p2jC體顯can protect 
malignant lymphoid cells from drug-induced apoptosis. It is well known that 
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P2jCipi/wafi was once perceived mainly as an anticancer protein because of its anti-
proliferation effects, but now it has been considered as an "antagonistic duality" with 
both pro-apoptosis and anti-apoptotic capability. Therefore, the implication of its 
contribution to MDR, just like TP5S, is not consistent. 
Furthermore, wild-type TP53 can repress expression of both the MDRl gene and 
MRP J gene (Chin et al., 1992; Nguyen et al , 1994; Strauss et al., 1995; Wang et al., 
1998; Zhou et al , 1998; Sullivan et al , 2000; Marroni et al., 2003), suggesting an 
association b etween TP53 and multidrug transporters. H owever, o ther studies have 
indicated conflicting results (Nicoletti et al., 2001; Sampath et al., 2001). Therefore, 
the precise mechanisms by which TP53 interacts with the classical MDR mechanisms 
still remain to be clarified. 
1.2.2.2. Anti-oncogene PTENmd drug resistance 
Another system influencing drug resistance is the signaling pathway which involves 
the PTEN gene. PTEN is the tumor suppressor with a sequence homology to tyrosine 
phosphatases and tensin, a protein associated with the actin cytoskeleton in focal 
adhesions (Li et al., 1997; Steck et al , 1997). The PTEN protein is capable of 
dephosphorylating both phosphotyrosine and phosphothreonine-containing substrates. 
The function of PTEN as a tumor suppressor is evidently connected with its ability to 
inhibit the activation of Akt, a serine-threonine kinase that is involved in the 
proliferative metabolic and antiapoptotic pathways (Maehama et a l , 1998; Di 
Cristofano et al., 2000; Huang et al., 2001). Thus, negative influence of PTEN on cell 
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survival can increase cell sensitivity to chemotherapy; whilst inactivation of PTEN 
can result in drug resistance. Indeed, it has been demonstrated that PZfiTV-deficient 
cells exhibit resistance to a number of apoptosis inducing injuries such as UV 
irradiation, TNF-alpha, cycloheximide, anisomycin, anthracycline, sorbitol and heat 
shock (Stambolic et al., 1998; Grunwald et al., 2002; Tanaka et a l , 2003; Zhou et a l , 
2003). In these resistant cells the activity and phosphorylation of kinase PKBIAkt 
were generally increased (Grunwald et al , 2002; Tanaka et al., 2003). 
1.2.2.3. Influence of BCL2 family on drug resistance 
Apoptosis or programmed cell death is considered as the outcome of a complex 
interplay of pro- and anti-apoptosis molecules (Korsmeyer et al., 1993; Adams et al , 
1998; Reed et al , 2000). Pro-survival BCL2 and its helpers compete with BAX and 
other proapoptosis proteins to regulate the discharge of proteins and release of 
cytochrome c from mitochondria, which in turn will activate 'initiator' caspases. 
Activation of the latter leads to a cascade that is directly related to specific apoptotic 
characteristics. 
BCL2 protein is able to inhibit the apoptosis induced by TP53 in response to 
genotoxic stress (Chiou et al., 1994). There are data showing that BCL2 
overexpression can result in the resistance of a cell to different drugs (Dive e t a l , 
1997; Fu et al., 1999; Perkins et al , 2000; Koukourakis et al., 2001; Itoh et a l , 2003). 
Therefore several strategies to reverse MDR phenotype by targeting BCL2 have 
received intense interest. For example, the suppression of proteins using antisense 
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oligonucleotides (ASOs) has shown quite effective in sensitizing the drug resistance 
in certain cancers (Tanabe et al., 2003). 
BAX have also suggested conferring drug resistance in several cases (Gallo et a l , 
2003). Zhang et al (2000) reported that loss of BAX alone is enough to induce the 
resistance to 5-fluorouracil in colon carcinoma cells. 
1.3. The chemotherapeutic agent doxorubicin 
Doxorubicin (DX) is a cytotoxic anthracycline antibiotic isolated from Streptomyces 
peucetius var. caesius. The molecular formula of DX is C27H29NO11.HCI, which 
consists of a naphthacenequinone nucleus linked through a glycosidic bond at ring 
atom 7 to an amino sugar, daunosamine (Figure 1.2). 
As one of first discovered anthracycline antibiotics, DX was developed in the 1960s 
and has been used in the treatment against a wide range of cancers since then (Carter 
et a l , 1975; Arcamone et al., 1985). The cytotoxic effects of DX are thought to be 
related to (1) its nucleotide base intercalation activity, which may inhibit nucleotide 
replication through affecting the action of DNA and RNA polymerases (Meriwether 
et al., 1972; Gabbay et al., 1976); (2) the cell membrane lipid binding activity of DX， 
which may affect a variety of cellular functions; (3) the interaction with 
topoisomerase II to form DNA-cleavable complexes appears to be another important 
mechanism by which DX exhibits its cytotoxic effect (Lothstein et al., 2001). Cells 
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treated with DX have been shown to manifest the characteristic morphologic changes 
associated with apoptosis or programmed cell death. 
Nevertheless, DX is toxic not only to cancer cells but also to normal cells. As a result, 
this gives rise to numerous side effects, such as cardiac toxicity. Enzymatic electron 
reduction of DX by a variety of oxidases, reductases and dehydrogenases generate 
highly reactive species including the hydroxyl free radical OH'. Free radical 
formation has been implicated in the cardiotoxicity by means of Cu (II) and Fe (III) 
reduction at the cellular level. Despite several attempts to reduce the toxicity of this 
drug, there is a serious obstruction to the successful treatment of cancer patients with 
DX due to the emergence of cancer cells which are refractory to chemotherapy. 
Extensive research has thus been conducted to overcome drug resistance to DX. 
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Figure 1.2. Structure formula of doxorubicin. 
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Chemically, doxorubicin hydrochloride is: (8S, lOS) - 10- [(3- amino- 2，3，6 -
trideoxy - .alpha. - L- lyxo -hexopyranosyl) oxy] - 8 - glycolyl -7，8，9，10 -




1.4. Aims of study 
Hepatic resection remains the only hope for long-term survival of patients with HCC. 
However, since the majority of patients are asymptomatic during the course of 
disease progression, this has rendered most patients not being diagnosed in time for 
curative surgery. Chemotherapy is therefore considered the primary management for 
more than 85% of HCC patients in Hong Kong. Doxorubicin (DX) and analogues are 
widely used first-line chemotherapeutic agents for the inoperable HCC patients. 
Despite the low 15-20% overall response rate, treatment with DX is associated with 
prolongation of survival and improvement in disease-related symptoms. The clinical 
behavior of HCC in response to DX administration has been shown to be variable. 
Most patients are either intrinsically resistant or develop resistance during the course 
of treatment. A better understanding on the genetic events that u n d e r l i e tumor 
resistance to this chemotherapeutic agent is thus important from a clinical standpoint. 
Cancer cell lines represent invaluable in vitro models in drug studies and are a proven 
resource for gene isolation. To model DX toxicity response，we have employed HCC 
cell lines, since it would not have been possible to utilize surgical tissues. In 
responding patients, the effect of DX will not have provided viable cells for genetic 
and expression analysis, while in non-responding patients curative surgery will 
unlikely have been offered. Whilst there are limited numbers of HCC cell lines 
available commercially, we have successfully established 6 cell lines from the 
tumorous liver tissues of patients, who underwent curative liver surgery for HCC at 
the Prince of Wales Hospital, Hong Kong. These cell lines, together with those 
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accessible commercially, represent a collection of in vitro systems that has enabled 
our molecular investigations of genetic changes associated with drug tolerance. In this 
thesis, we propose to narrow down the target regions, at the genomic level, by 
Spectral Karyotyping (SKY). Our underlying hypothesis is that insensitivity to DX 
chemotherapy in HCC is associated with intrinsic genetic alterations of the tumor. 
Thesis objectives: 
(1) To examine the role of well recognized MDR mechanisms in the intrinsic 
doxorubicin resistance of HCC cells. 
(2) To identify genomic instability associated with doxorubicin resistance in HCC 
cells. 
(3) To elucidate for drug resistance genes by means of transcriptional mapping using 
the cDNA microarray technology. 
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CHAPTER TWO 
MATERIALS AND METHODS 
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2.1 Cell culture 
2.1.1 Cell lines and cell culture 
A total of nine human HCC cell lines were studied. Three liver cancer cell lines 
(HepG2, Hep3B and PLC/PRF/5) were purchased from American Type Culture 
Collection (ATCC) and cultured in DMEM (Gibco) supplemented with 10% fetal calf 
serum, 2mM L-Glutamine and lOOU Penicillin-streptomycin (table2.1). Six in-house 
established HCC cell lines, HKCI-Cl, -C2, -1, -2’ -3 and -4，were developed from 
the tumorous liver tissues of HCC patients who underwent curative surgery for HCC 
at the Prince of Wales Hospital, Hong Kong (Pang et al., 2000; Pang et a l , 2002). 
The clinical information on these patients was list in Table 2.2. The HKCI series of 
cell lines were cultured in AIM-V medium (Gibco Invitrogen Corporation, MD. USA) 
supplemented with 10% fetal calf serum, lOOU Penicillin-streptomycin, 2mM L-
Glutamine (Gibco) and ITS supplement (Sigma Chemical Company, MO, USA). 
Cultures were maintained in a humidified chamber in 5% CO2 atmosphere at 37�C. 





























































































































































































































































































































































































Materials and Methods 
2.1.2 Subculture 
The cell monolayer was examined daily and subcultured when they reached about 
80% confluence. Cells were first washed by 1 x PBS (Sigma) and dislodged from the 
flask by incubation with 2 mL trypsin-EDTA solution (0.005% Trypsin, 0.053nM 
EDTA, Gibco) at 37°C for 2-5 minutes. An equal volume of pre-warmed complete 
culture medium was added to inactivate the trypsin. Cell collected suspensions were 
subjected to centrifugation at l，000rpm for 5 minutes. The trypsin-EDTA supernatant 
was then aspirated and pre-warmed complete culture medium was added to resuspend 
the cells. Twenty-five mL of this cell suspension was added to a new 25cm flask and 
then incubated at 37°C until the cell monolayer reached about 80% confluence before 
another round of subculturing was performed. 
2.1.3 Cryopreservation 
Procedure of cryopreservation was exactly the same as subculture, except that the 
cells were resuspended by pre-warmed cell culture freezing medium (culture medium 
supplied with 50% FCS and 10% DMSO (Sigma)) instead of complete culture 
medium at a density of approximately 1 x 10^ cell/mL. The cells in freezing medium 
were transferred to cryogenic storage vials and cooled in the freezing bucket at -80°C 
overnight. After that, the vials were taken out of freezing bucket and stored at - 8 0 � C 
ultra-freezer. 
-23-
Materials and Methods 
2.1.4 Recovery of cryopreserved culture 
The frozen cells were removed from -80°C ultra-freezer and thawed quickly in a 
37°C water bath. The cells were firstly washed with two mL pre-warmed culture 
medium to remove the DMSO. After centrifugation at 1,000 rpm for 5 minutes and 
removal of supernatant, the cell pellets were dispersed with 5 mL full medium and 
seeded in 25 cm^ culture flasks. The cells were allowed to attach for 24 hours, after 
which the medium was removed and replaced with 5 mL pre-warmed fresh medium. 
2.1.5 Cell number counting 
Briefly, a uniform cell suspension to be counted was first prepared. A small sample of 
cell suspension diluted at 1 : 5 in 0.4% (w/v) trypan blue was prepared and dropped 
under the coverslip on the hemacytometer chamber. The hemacytometer was then put 
on the s tage o f a n i nverted m icroscope. U sing 1 00 x m agnification, c ell c ounts i n 
each of the four comer squares were recorded by a hand-held counter. Finally, the 
total number of cells per mL and total number of viable cells per mL were calculated 
(Figure 2.1). 
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Figure 2.1 Hemacytometer Counting Chamber 
^Coun t i ng Grids 
z Z / ( 9 squares each) 
i f / 
1 2 3 10 11 12 
Sample 1 ^ 4 5 6 13 14 15' , Sample2 
7 8 9 16 17 [ i s ] 
u \ 
p f ^ p p y Y n r n m v s f f l i f f l m s F f P n T I counting 
Squares 
{Area under coverslip} 
Calculate the number of cells per mL in the original culture as follows: 
The total number of cells per mL 
4氺 
=Average cell count in one square x dilution factor x 10 
The total number of viable cells per mL 
氺氺 *** 4* 
=Average viable cell count in one square x dilution factor x 10 
The hemacytometer well is 3 mm x 3 mm. The total volume of one square is 
1 mm X 1 mm X 0.1 mm = 0.1 |iL (1x10"^ mL). 
** Viable cells do not stain with trypan blue and therefore appear to be white 
under the microscope. 
*** Dilution factor = Total volume (cell suspension sample + trypan blue solution) 
/ Volume of cell suspension sample. It equals to 5 in this thesis. 
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2.2 MTT experiments 
MTT assay is widely used in chemosensitivity testing of tumor c ell 1 ines in many 
laboratories. MTT agent is a yellow water soluble tetrazolium dye that can be reduced 
by viable but not dead cells. The action of dehydrogenase enzymes in mitochondrion 
generate purple formazan product that is insoluble in aqueous solutions. The amount 
of formazan formed is directly proportional to the mitochondrial enzyme activity and 
therefore the number of viable cells in a given cell line. It can be determined 
spectrophotometrically once solubilized in a suitable solvent such as DMSO. Details 
on the MTT procedure is described in the following section 2.2.1. 
2.2.1. Determination of cell seeding density 
Since different cells possess different proliferation, prior to the initiation of cytotoxic 
study, the seeding density for each cell line was estimated so that the cells will remain 
in exponential phase throughout of the 4-day experimental period. Briefly, cells were 
seeded in 96-well culture plates at increasing densities from 0 - 10,000 cells per well. 
Five-replicate wells were analyzed for each seeding density. After 24 hours of 
incubation, fresh medium was delivered at the volume of 200 i^L to each well. 
Incubation was continued for 3 days. The culture medium was removed and 50 \iL of 
MTT (0.1 mg/mL, Sigma) was added to each well. Plates were incubated for an 
additional 4 hours in the dark at 37 °C. After that, the MTT solution was aspirated 
from the wells and 100 [lL of DMSO was added. The plates were allowed to stand for 
about 2 hours at room temperature. The absorbance of colorimetric product was then 
read at 570 nm in a Rainbow Reader (TECAN Austria Ges.m.b.H) with the reference 
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wavelength of 630 nm. The subsequent data assays were performed with EXCEL. The 
seeding density was determined by 50% confluency compared to the wells with the 
highest seeding density (10,000 cells/well). 
2.2.2 Cytotoxic assay 
The cytotoxicity of Doxorubicin (DX) was evaluated colorimetrically by MTT assay. 
Briefly, cells were seeded in 96-well culture plates at a density as determined from 
above. After 24 hours incubation, freshly prepared DX (Pharmaceutical Laboratories, 
Unterach, Austria) was delivered in 12 sequential dilutions of 0, 0.00172, 0.0172, 
0.0862, 0.172, 0.862，1.72, 8.62, 17.2, 86.2, 172, 345 |liM. Five-replicate wells were 
analyzed for each concentration. Incubation continued for 3 days (Li et al, 2001). 
MTT assay procedure was the same as the methods mentioned for cell seeding 
density determination. The MTT assays were repeated 3 times for each cell line. The 
IC50 values from the cytotoxic assay were extrapolated by the Prism software version 
3.1 (Abacus Concepts Inc., Berkeley, CA). The IC50 values were defined as the 
concentration of cytotoxic drug causing 50 % inhibition of cell growth, as compared 
to the untreated control. 
2.3. Spectral Karytyping (SKY) 
SKY is a molecular cytogenetic technique that permits the simultaneous visualization 
of all human chromosomes in different colors, considerably facilitating karyotype 
analysis. Our protocol was carried out according to Schrock's method (Schrock et al., 
1996) with modifications described by Wong (Wong et al., 2000). 
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2.3.1. Pretreatment of chromosome slides for SKY 
Metaphase chromosome spread on the glass slides were first equilibrated in a coplin 
jar containing 2 x SSC for 1 hour at 37�C. After that, 100|^g/mL RNase (Amersham 
Life Science) in 2 x SSC was added. Slides were then incubated in a moist 
hybridization chamber at 37�C for 1 hour following three washes in 2 x SSC at room 
temperature for 5 minutes each. Dehydration procedures were performed in ethanol 
series of 70%, 80%, and 100% for 2 minutes each. The slides were finally air dried at 
room temperature and stored at -20°C until use. 
Before hybridization, slides were treated with 10 |ig/mL Pepsin in 30mL pre-warmed 
0.01 M HCl at 37�C for 2-5 minutes. Slides were then washed twice in 2 x SSC for 4 
minutes each and dehydrated in ethanol series of 70%, 80% and 100% for 2 minutes 
each. Chromosome morphology was then evaluated and area for hybridization was 
selected. 
2.3.2. Hybridization 
SkyPaint™ probe mixture (Applied Spectral Imaging, Ltd. Migdal Haemek, Israel) 
was denatured at 85°C for 5 minutes and immediately put into ice for 3 minutes 
followed by pre-annealing procedure at 37°C for 30 minutes. At the same time, slides 
were denatured with 120 i^l of 70% deionized formamide/2 x SSC at 50-70°C on a 
hot plate for 1.5 minutes. Following dehydration through the cooled ethanol series of 
70%, 80% and 100% for 2 minutes each, 10|iL pre-annealed probe mixture was 
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applied onto denatured metaphase chromosomes and then covered with a coverslip. 
Coverslip was sealed completely with rubber cement, and hybridization was 
performed at 37°C in a humidified hybridization chamber for 3 days. 
2.3.3. Detection 
After hybridization, rubber cement surrounding coverslip was carefully removed by 
forceps. Post-hybridization washes were performed in 50% fomiamide/2 x SSC (pH 
7.5) and 1 x SSC (pH 7.5) at 45�C for 5 minutes each with gentle agitation. Next, 
blocking solution was applied at 3 7 T for 30 minutes and then washed in 4 x 
SSC/0.1% Tween20 for 5 minutes. Biotinylated probes were then visualized using 
avidin Cy5 (Amersham Life Sciences, Buckinghamshire, UK) and dig-labeled probes 
by incubation with an anti-mouse digoxin antibody (Sigma) followed by a goat anti-
mouse-antibody conjugated to Cy5.5 (Amersham Life Sciences). Antibodies were 
diluted at 1:200 in 4 x SSC/0.1% Tween20. The incubations were performed for 45 
minutes each at 37°C followed by three washes in 4 x SSC/0.1% Tween20 for 5 
minutes each. Chromosomes were then counterstained with DAPI in anti-fade 
solution (Vector Shield, Vector Laboratories, Burlingame, CA) prior to image capture. 
Images were acquired using a SD200 Spectracube (Applied Spectral Imaging, Migdal 
Haemek, Israel) mounted on a Leica DMRXA microscope. Acquired images were 
analyzed by SkyView software v. 1.6. A rearrangement was considered if it was 
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identified in 2 or more cells per case. Chromosomes were karyotyped according to the 
International System for Human Cytogenetic Nomenclature (ISCN，1995). 
2.4 Positional expression profiling 
cDNA microarray technology is a powerful technique that is recently developed to 
analyze thousands of genes in a single experiment. The principle of the technique is 
showed in Figure 2.2. In this thesis, due to the importance of chromosome 10 found 
in DX resistance of HCC identified by SKY analysis, a high resolution transcriptional 
mapping analysis on chromosome 10 was conducted using the microarray analysis. 
The microarray experiments were carried out according to the protocol of the 
Microarray Center, University Health Network, Toronto, Canada 
(http://www.uhnres.utoronto.ca/services/microarray/protocols/). 
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Figure 2.2. The basic principle of microarray 
Hybridisation Results delivery 
(Normal) (Tumor) Scamiiiig (lecture) 
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T tnmscr^tion • 
E i^S ！ : - 5 ! J.: 
* • * * • Results analysis 
DNA microarrays allow for rapid measurement and visualisation of differentially 
expression between genes at the whole genome level. The figure described the major 
steps involved in this process: hybridization, slide scanning and data analysis 
(Stephane Le Crom and Philippe Marc, Molecular Biology Program and Department 
of Physiology and Biophysics, University of Iowa, Iowa City) 
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2.4.1. RNA extraction 
Total RNA was extracted from 4 cell lines, HKCI-1, -2，-3 and -CI, that displayed the 
highest DX resistance using the TRIZOL reagent (Life Technologies, Ic. USA). 
Firstly, cells were harvested and washed three times in DEPC treated 1 x PBS and 
then lysated directly in a culture dish by adding 3 mL of TRIZOL Reagent. The cell 
lysate was transferred by passing several times through a pipette into an RNase free 
tube. Chloroform at 0.6 mL was then added following centrifugation at 12,000 x g for 
25 minutes at 4 � C . After that, the aqueous phase which should exclusively contain 
RNA was transferred into a fresh tube. The RNA was precipitated by adding 1.5 mL 
isopropyl aIcohol followedby centrifugation at 1 2,000 x g for 20 minutes a14°C. 
RNA pellet was washed with 75% ethanol. After centrifugation at 7,500 x g for 15 
minutes at 4°C, supemant was discarded and briefly dried RNA was dissolved in 
DEPC treated ddH20. At the end of the procedure, the quantity and purity ofmRNA 
was determined by electrophoresis (Figure 2.3), and the absorbance at 260nm and 
280nm was measured. The absorbance ratio of 260nm to 280nm (A260/A280) of total 
RNA extracted ranged from 1.8-2.0. The RNA was stored at -80°C until analysis. 
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Figure 2.3. RNA Extraction from HCC cell lines 
Lane 1 Lane 2 Lane 3 Lane 4 
After isolation of RNA from the HCC cells, gel electrophoresis was done to 
determine RNA quality and DNA contamination. The wells from the left are HKCI-1, 
-2, -3 and CI RNA, respectively. There was no sign of DNA contamination and no 
smeared bands at the bottom that indicated RNA degradation. 
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2.4.2. Reverse transcription and cDNA labeling 
Twelve ^g of total RNA from HCC cell lines and pooled normal liver RNA from 
three individuals (Ambion, Austin, TX; Clontech Laboratory Inc., Palo Alto, CA; and 
Strategene, La Jolla, California, USA) were labeled with Cy3 and Cy5, respectively. 
The RT reaction volume at 40 \iL was prepared by adding 8.0 |aL 5 x First Strand 
reaction buffer (Superscript II，Invitrogen), 1.5 \iL AncT mRNA primer (5'-T20VN, 
100 pmol/mL), 3.0 pL dNTP (6.67 mM each ofdATP, dGTP, dTTP), 1.0 |aL 2 mM 
dCTP, 1.5 jaL 1 mM Cy 3 or Cy 5-dCTP (Amersham Pharmacia Biotech), 4.0 [lL 0.1 
M DTT and made up to the volume by nuclease-free water (Sigma). Following 5 
minutes at 65°C, and then 5 minutes at 42°C, 2 i^ L of reverse transcriptase 
(Superscript II，Invitrogen) was added and the labeling reaction was conducted at 42 
°C for 2-2.5 hours in the dark. Four |j,L of 50 mM EDTA (pH 8.0), and 2 i^L of lOM 
NaOH were added to stop the reaction. The reaction mix was then incubated at 65°C 
for 20 minutes to hydrolyze the remaining RNA. At this point, the control and test 
cDNAs were combined. Eight p,L of 5 M acetic acid was added to ensure the solution 
is neutralized (pH 7.0). 
2.4.3. Probe purification and hybridization 
The probe purification was performed by using UAmicon® Microcon® PCR 
Centrifugal Filter Devices according to the manufacture's instruction. Briefly, 400 |aL 
of nuclease-free H2O (Sigma) and 100 \iL cDNA products were transferred to the 
sample reservoir without touching the membrane. The solution was mixed by 
pipetting up and down several times followed by spinning at 13,500 rpm in a 
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microcentrifuge for 15 minutes to reduce sample volume to 5 \iL or less. Then, 
nuclease-free water (Sigma) was carefully added to the reservoir avoiding touching 
the membrane surface. After incubating at room temperature for 30 seconds, the 
column was transferred to a fresh tube and spun at 13,500 rpm for 2 minutes to 
collect 5-6 fiL purified labeled-cDNA. 
A mixture containing 70 [iL of DIG Easy Hybridization solution (Roche), 4 i^L of 
yeast tRNA (Invitrogen; 10 mg/mL) and 2 i^L of calf thymus DNA (Sigma; 10 
mg/mL) was pre-warmed to 65°C and added to the purified labeled cDNA to an 
approximate final volume of 80 |iL. The hybridization solution with the labeled-
cDNA was further incubated at 6 5 � C for 2 minutes, and cooled to room temperature. 
Thereafter, the slides were carefully placed in a hybridization chamber and incubated 
on a level surface at 37 °C over two nights. 
After hybridization, slides were washed three times at 4 5 � C with gentle agitation in 
pre-warmed 1 x SSC/0.1% SDS (pH 7.0) for 10 minutes each and then gentle rinsing 
in 1 X SSC (pH 7.0) twice for 1-2 minutes each. Slides were then spun dried at 850 
rpm for 5 minutes in a slide box lined with Whatman paper. Hybridized arrays were 
kept in the dark and scanned immediately. 
2.4.4. Image acquisition and data analysis 
Image acquisition: Duplicate array hybridizations were carried out for each test 
sample with a dye switch performed in the second experiment. The fluorescent images 
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were scanned by a ScanArrray 5000 scanner (GSI Lumonics, Packard Bioscience, 
Pangboume, UK). The raw images acquired were analyzed by the GenePix Pro 4.0 
(Parkard Biochip Technologies). The intensity of each fluorescence signal was 
quantified and the data saved as GPR file for further Normalization, Project and 
Profiler analysis by the Normalise Suit (version 1.63) provided by the Microarray 
Center at Ontario Cancer Institute (OCI)，University Health Network (UHN). 
Normalization: The background of the microarray image is often not uniform across 
the entire array or within subarray (spots in groups of grids); however "subarray 
normalization" has consistently been reported a better normalised distribution than 
"entirearray" normalization. Therefore, array results obtained in this thesis were 
normalized by subarray normalization. The 532 nm (Cy3) channel was equalized with 
respect to the 635 nm (Cy5) channel. After normalization, duplicate spots from the 
microarray are averaged together. The resulting ratio of 635 nm (Cy5) over 532 nm 
(Cy3) with >= 2-fold was considered for over-expression and <= 0.5-fold considered 
for under-expression. 
Project and profiler. Using project, two or more normalized replicates of an 
experiment, including reverse labelings, can be grouped together as a project. The 
Profiler procedure was then performed to integrate identified signal ratios with 
interesting physical map locations of cDNAs in sequential order of megabase 
distances (http://www.utoronto.ca/cancyto/). 
-36-
Materials and Methods 
2.5 Quantitative RT-PCR 
2.5.1. RNA extraction 
As mentioned in the chapter 2.4.1. 
2.5.2. Primer design 
Primers were designed using the web-based PrimerS software 
(http://www.broad.mit.edu/cgi-bin/primer/primer3_www.cgi) on the basis of genes 
full sequences obtained from Human BLAT Search (http://genome.ucsc.edu/cgi-
bin/hgGateway). Whenever possible, primers were designed to span at least one 
intron. Each primer was designed to produce approximately 100-bp amplicon. Blast 
search from GenBank database (http://www.ncbi.nlm.nih.gov/BLAST) revealed that 
primers designed were gene specific. The primers designed for the candidate genes 
are listed in table 2.3. 
2.5.3. Reverse transcription 
Two [ig of total RNA was subjected to cDNA synthesis in 100 jiL of reaction mixture 
containing Taq Man RT buffer (Applied Biosystems, Foster City, CA, USA), 5.5 mM 
MgCl2, 500 uM dNTP, 2.5 uM random hexamers, 0.4U/ |xL RNAase inhibitor, and 
1.25 U/jiL MultiScribe™ reverse transcriptase. The RT reaction was performed in 
sequencial order of 10 minutes at 25�C，30 minutes at 48°C, and 5 minutes at 95°C. 
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Table 2.3. Primers used for Quantitative RT- PCR 
Genes Primer Sequence 
ECHS1 5'-TACCAGCCAGTGCCTGCATCT-3' (Sense) 
5'-ATGGAGTGTAGGTGGGGACA-3'(Anti-sense) 




MRPI 5'-TACCTCCTGTGGCTGAATCTGG-3' (Sense) 
5'-CCGATTGTCTTTGCTCTTCATG-3'{Anti-sense) 
TP53 5'-CTGCTCAGATAGCGATGGTCTG-3' (Sense) 
5'-TTGTAGTGGATGGTGGTACAGTCA-3'(Anti-sense) 
P21 5'-CGCTAATGGCGGGCTG-3' (Sense) 
5'-CGGTGACAAAGTCGAAGTTCC-3'(Anti-sense) 
BAX 5.-TCCCCCCGAGAGGTCTTTT-3. (Sense) 
5'-CGGCCCCAGTTGAAGTTG-3'(Anti-sense) 
BCL2 5'-ATGTGTGTGGAGAGCGTCAA-3' (Sense) 
5'-ACAGTTCCACCAAGGCATCC-3'(Anti-sense) 
PTEN 5'-GCGAGTTGCACAATATCCT-3' (Sense) 
5'-TCGTCCCTTTCCAGCTTTAC-3'(Anti-sense) 
MGMT 5'-AATGAGAGGCAATCCTGTCCC-3' (Sense) 
5'-AAGCCATTCCTTCACGGCCA-3'(Anti-sense) 
GAPDH 5'-GAAGGTGAAGGTCGGAGT-3' (Sense) 
5'-GAAGATGGTGATGGGATTTC-3'(Anti-sense) 
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2.5.4. Quantitative PGR 
All quantitative PCRreactions wereperformed in a 25 [iL mixture containing 1/20 
volume of single complementary DNAs (cDNAs) preparation (1 )iL), 1 x SYBR Green 
buffer (PE Applied Biosystems), 4 mM MgCli, 0.2 [iM of each primers, 0.2 mM each 
of dATP, dCTP, and dGTP mix, 400|aM dUTP and 0.025 Unit of AmpliTaq Gold® 
thermostable DNA polymerase (Applied Biosystems). The emission intensity from 
SYBR green binding to double-stranded DNA was detected by the iCycler detection 
system (BioRad Laboratories, Hercules, CA). The thermal cycling conditions 
consisted 10 minutes 95°C, followed by 40 cycles of 95°C for 15 seconds and 60°C for 
MDRJ, MRP], TP53, BCL2, BAX and P21 or 55°C for PTEN, MGMT, CGI-18 and 
ECHSl for 1 minute. 
The fluorescence threshold value was calculated using the iCycle iQ system software. 
Briefly, the amount of PGR product is measured by determining the first cycle of the 
logarithmic phase of amplification, called threshold cycle (Q), which is dependent on 
the cDNA initial concentration. Samples with a higher concentration of starting 
material enter the linear phase earlier than samples with a lower concentration of 
starting material and therefore have a smaller Q. Threshold cycles were averaged 
from triplicate reactions. The following formula was used to calculate the relative 
amount of the transcript of interest in the HCC sample (T) and 3 individual normal 
human liver cells (Ambion; Clontech Laboratory Inc., Strategene) (N)，both of which 
were normalized to the housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase {GAPDH) levels. 
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2 -AACt二2 - [ACt (T) - ACt (N)] _ 2 - [(Ct (T) - Ct (GADPH)) - (Ct (N) - Ct (GADPH)] 
ACt is the difference in Ct between the gene of interest and GAPDH, for sample T, 
A ACt is the difference in ACt between the sample (T) and normal control (N). 
In all experiments, samples containing no template were included to serve as negative 
controls. The specificity of the amplicons was confirmed by melting curve analysis 
(Figure 2.4). 
2.6. Statistical analysis 
Statistical correlations between IC50 values with individual chromosomal changes and 
candidate gene expressions were assessed by the Pearson 's correlation coefficients 
using the SPSS software version 10.0 (Chicago, IL, USA). A P-value < 0.05 was 
considered significant. 
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Figure 2.4. Melting curve o f Quantitative RT-PCR for sample genes. Melting 
curve analyses of the amplified PGR products revealed predominately a single 
product, (a). Melting curve analysis of the MDRl (1)，MRP I (2) and GAPDH (3) 
amplicons. (b). Melting curve analysis of the TP53 (1)，BCL2 (2) and GAPDH (3) 
amplicons. (c). Melting curve analysis of the CGI-18 (11), ECHSl (2) and GAPDH (3) 
amplicons. 
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Figure 2.4. Melting curve of Quantitative RT-PCR for sample genes. 
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In this chapter, the intrinsic DX resistance behavior in HCC was examined in a panel 
of HCC cell lines. DX tolerances on these HCC cells were determined by MTT assay 
and IC50 values were identified for each cell line. The role of several well-
characterized candidate drug resistant genes was investigated by quantitative RT-PCR. 
These genes included those involved in the classical MDR mechanisms {MDRl and 
MRP1\ apoptosis and cell cycle regulations {TP53, BCL2, BAX and P21), DNA 
repair (MGMT) and cell survival pathway (PTEN). In order to gain insight into the 
karyotypic abnormalities associated with drug resistance, Spectral Karyotyping (SKY) 
was employed to provide a comprehensive overview on the chromosome changes 
persistent in the drug resistant lines. The chromosome loci defined were further 
investigated for underlying deregulated genes by positional expression profiling. 
3.1. Doxorubicin resistance in HCC cell lines 
Since different cells possess different proliferation, prior to the initiation of cytotoxic 
study, the seeding density for each cell line was estimated so that the cells will remain 
in exponential phase throughout of the 4-day experimental period. The determined 
cell seeding density for 9 cell lines was found to range from 2000-4000 / well. The 
growth curves for these cell lines are showed in Figure 3.1. 
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The cytotoxic effect of DX on 9 HCC cell lines indicated varying responses that 
ranged from sensitive to resistant (Figure 3.2). The IC50 values determined ranged 
from 0.07|xM to 3.55)aM with a maximal difference of 50.7-fold suggested (Table 
3.1). A median IC50 value was suggested at 0.95^iM (Table 3.1)，using the value as a 
cut-off, four cell lines, HKCI-1, -2，-3 and -CI, was considered as relatively more 




Figure 3.1. Seeding density determined by MTT. Prior to cytotoxic analysis, cell 
seeding densities for nine cell lines were determined by MTT assay, (a) Seeding 
density determined for HKCI-1, HKCI-2 and HKCI-3 (b) Seeding density determined 
for HKCI-4, HKCI-Cl and HKCI-C2 (c) Seeding density determined for HepG2, 
Hep3B and PLCS. 
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Figure 3.1a. Seeding density determined by MTT 
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Figure 3.1a. Seeding density determined by MTT 
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Figure 3.1a. Seeding density determined by MTT 
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The results shown are from at least three independent experiments. 
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Table 3.1. The IC50 values of DX on HCC cell lines 
Cell Lines I C 5 0 ( _ 
HKCI-1 1.95 ±0.17 
HKCI-2 3.55 士 0.47 
HKCI-3 3.28 士 0.07 
HKCI-4 0.95 ±0.10 
HKCI-Cl 1.66 士 0.19 
HKCI-C2 0.43 ± 0.22 
HepG2 0.07 士 0.03 
Hep3B 0.09 士 0.02 
PLCS 0.14 士 0.03 
The IC50 values of DX obtained with MTT assay for HCC cell lines were presented 
as mean 士 SD. The results shown are from at least three experiments. 
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Figure 3.3. Growth kinetics of HCC cell lines treated with doxorubicin 
Nine HCC cell lines were incubated in medium containing DX that ranged from 0 -
345 |aM. The cell viability in increasing concentrations of DX was determined by 
MTT assay. The survival factor was determined as IC50, which is shown by the lines 
drawn in the figure, (a) IC50 values determined for HKCI-1, HKCI-2 and HKCI-3 (b) 
IC50 values determined determined for HKCI-4, HKCI-Cl and HKCI-C2 (c) IC50 
values determined determined for HepG2, Hep3B and PLCS. 
-52-
Results 
Figure 3.3a. Growth kinetics of HCC cell lines treated with Doxorubicin 
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Figure 3.3a. Growth kinetics of HCC cell lines treated with Doxorubicin 
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Figure 3.3a. Growth kinetics of HCC cell lines treated with Doxorubicin 
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3.2. Candidate drug resistant genes 
The classical MDR transporters {MDRl and MRP1\ apoptosis and cell cycle 
regulators {TP53, BCL2, BAX and P21) were examined by quantitative RT-PCR. 
These genes were found to express in all cell lines studied irrespective of their drug 
resistance status (table 3.2). The level of gene expression and the results from 
statistical analysis are summarized in table 3.2. 
To evaluate whether the expression of ABC transporters might be predictive for drug 
sensitivity, we correlated MDRl and MRPI expression levels with IC50 values. 
However, the influence of MDRl and MRPI levels on the intrinsic drug resistance 
was not suggested (p>0.05). 
We performed a similar analysis to assess the impact of several apoptosis associated 
genes on IC50. A significant inverse correlation between BAX expression and IC50 
was observed, with Pearson's correlation coefficient -0.877 (P = 0.002). The 
implication of other candidate genes, TP53 and BCL2, on the intrinsic drug resistance, 
on the other hand, was not suggested (P>0.05). Furthermore, no significant 
association of IC50 with the ratio of BAX to BCL2 was suggested. We also attempted 
correlation on the expression of cell cycle regulator P2I in these cell lines. An 
correlation between down-regulated P21 expression and increasing IC50 values was 





























































































































































































































































































































































































































































































































3.3. The roles of chromosomal instability 
The possible molecular changes underlying the observed DX resistance were also 
investigated at the chromosomal level by SKY. A list of all chromosome aberrations 
identified by SKY was present in table 3.3. Numerical anomalies in 9 cell lines 
ranged from a near-diploid to hyper-hexaploid karyotype. Although aneuploidy is one 
of hallmarks for genetic instability, we found no evidence of association between 
chromosome aneuploidy and drug resistance (P�0.05). Closer examination on the 
individual chromosome aberrations suggested a strong linear correlation between 
frequent chromosome 10 abnormalities and increasing DX IC50 values (r=0.815’ 
P=0.007) (Table 3.4). Although translocation is the most common chromosome 10 
aberration observed, we found neither recurrent translocation nor consistent 
breakpoints that could be defined from the inverted DAPI image. Examples of 
chromosome 10 aberrations found in HKCI-3 and Hep3B are shown in Figure 3.4 and 
Figure 3.5, respectively. In an attempt to further elucidate for the underlying altered 
gene expression on chromosome 10’ transcriptional mapping by microarray was 
performed on 4 cell lines (HKCI-1, -2，-3 and -CI) that displayed the highest IC50 
values (figure 3.6). 
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Table 3.3. SKY analysis on HCC cell lines 









































cell lines ploidy Structure Aberrations based on SKY 
ins(8)t(8;12;8)(8pter-^ q23::12q13"^ q22::8q24.1 今 qter) 
dic(8;10)t(8;11;10)(8pter-> q12::11q12-> q25::10p11.2^qter) 
der(8)t(8;12;8;2)(8pter^ q24.1::12q14-> q23::?pq8::2q34-> 
qter) 















der(2)t(2;3)(p25;p12) « ^ ‘ � 













der(13)t(13;19)(q10;p10) « « � ‘ � 





dup(1)(pter-> p12::p12-p22::p22-^ p12) 
der(1)t(1;5)(q10;q23) 
der(1)t(1;17)(1qter-> p21::17q22 - > q12) ,—— 
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der(12)t(8;12)(8qter - > q11.2::12p11-> q12) 
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3.4. Candidate resistance genes identified in chromosome 10 
Transcriptional mapping on chromosome 10 was performed on microarray slides that 
contained 538 cDNA clones which spanned an average resolution of 180kb along 
chromosome lOp and lOq (Ontario Cancer Institute, Toronto, Canada). Profiling 
along the physical map location of individual cDNA clones suggested a number of 
candidates with differentially expressed up- and down-regulation ratios. Nonetheless, 
only 2 genes, CGI-18 (10q22.1) and ECHSI (10q26.2), demonstrated consistent 
mRNA down-regulation. An average CGI-18 reduction fold of 9士3.2 (mean士SD) and 
ECHSI 6.8士6.6 was suggested (Figure 3.7). To substantiate the expression changes 
identified from array hybridization, quantitative RT-PCR for the mRNA levels of 
CGI-18 and ECHSI was examined in the 4 DX resistant cell lines (HKCI-1, -2，-3 
and -CI). Down regulation of the two candidate genes at an average fold reduction of 
15.1 士2.4 and 354士260 respectively was indicated from quantitative RT-PCR, 
suggesting an agreement on their repressed expressions between array hybridization 
and PCR quantification (Figure 3.7). Further statistical correlation between the 
quantified expression levels of CGI-18 and ECHSI in the 9 HCC cell lines and their 
corresponding DX IC50 value suggested a significant association between a reduced 
ECHSI expression and DX resistance (r=-0.744; P=0.021). 
Two candidate resistance genes on chromosome 10，PTEN (10q23.3) and MGMT 
(10q26) with a proposed role in intrinsic DX resistance were also investigated. The 
gene expression levels of PTEN and MGMT as determined by quantitative RT-PCR 
and their correlations with IC50s are shown in table 3.5. Our results indicated that 
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although both genes displayed common down-regulations in the 9 HCC cell lines, no 
significant correlation with drug resistance was indicated (P>0.05). 
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Figure 3.6. Gene expression profiling by cDNA microarray (a) cDNA microarray 
image. Each cDNA clone is printed in duplicate on the OCI (Ontario Cancer Institute) 
microarray slide. Red spot (Cy3) indicates upregulation of gene expression and green 
ones (Cy5) suggest down regulation, (b) Linear scatter plot of gene expression 
determined from HKCI-Cl. 
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Figure 3.6. Gene expression profiling by cDNA microarray 
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Although the precise nature of MDR phenotype remains unclear, it is common for 
HCC cells to become multi-drug resistant while normal tissues are sensitive to the 
toxic effects of chemotherapy (Duesberg et al., 2001). A likely explanation for this 
phenomenon is that cancers arise after prolonged premalignant state, which provides 
opportunity to sustain multiple genetic 'hits'. The cancer genome is therefore 
characterized by genetic instability and complex aberrations (Knudson et al , 2001). 
As a consequence of genetic lesions accumulation that involves inactivation of tumor 
suppressors and activation of dominant-acting genes, the genomic aberrations 
acquired would provide an intrinsic drug resistance property. On the other hand, in 
the circumstance of normal tissues, resistance does not arise because the mutation rate 
is too low to permit defects in the genetic elements that control drug sensitivity. 
Cytogenetic and molecular studies have traditionally provided clues concerning the 
nature of chromosomal and genetic alterations associated with tumor characteristics. 
In this study, in order to gain insight into the repertoire of intrinsic chromosomal 
abnormalities that might have contributed to the DX resistance, S KY analysis was 
employed. Nonetheless, SKY is a purely cytogenetic analytical method; the result 
does not lead directly to gene isolation. Recent development of cDNA microarray 
technique, in contrast, may enable the rapid identification of differentially expressed 
genes between a test and a reference sample (DeRisi et al., 1996). However, 
screening hundreds of the differentially expressed genes that could be potential 
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targets is a challenging task. Therefore, extensive prioritization will be necessary 
before selecting the new genes for further analysis. The application cDNA 
microarrays to the analysis of tumors that have been previously cytogenetically 
characterized could therefore be very informative for identification and prioritization 
of target genes. In this thesis, SKY data determined has hence been integrated with 
the microarray expression results with an aim to facilitate the identification of 
potential drug resistance related genes. The findings of candidate genes from 
microarray were further validated individually by quantitative RT-PCR. 
4.1 In vitro cell models facilitate drug resistance investigations 
As a starting p oint, immortalised cell lines derived from cancer cells are ideal for 
MDR studies. Cultured cell lines provide homogenous cell populations that are 
convenient to use and provide a permanent window into the cell that can be 
dynamically examined. In addition, as opposed to methods aimed at measuring a 
single drug-resistant mechanism, over the years various in vitro drug resistant assays 
have been developed with the ultimate goal of predicting clinical drug resistance and 
tailoring chemotherapy for individual patients. Such assays have the theoretical 
advantage of measuring the sum of MDR mechanisms operative in a given cell 
population. Indeed, recent findings on the drug resistance mechanisms by in vitro cell 
models raise new hope in treating cancer patients who develop resistance to 
chemotherapy. However, all significant in vitro findings must be ultimately validated 
through clinical trials. Due to the limited availability of clinical specimens, it is 
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impractical to simultaneously apply multiple large-scale genome-wide analysis and 
molecular techniques directly on the limited amounts clinical samples. Therefore, cell 
responses in vitro under the treatment of cytotoxic reagents have demonstrated an 
undoubted role in the investigation of cellular drug resistance mechanisms. 
A number of cell lines from the tumorous liver tissues of HCC patients have been 
developed in our laboratory. In an attempt to examine the genetic changes associated 
with MDR phenotype, six in-house cell lines and 3 ATCC cell lines that demonstrated 
intrinsically different response to DX were investigated. The IC50 values determined 
ranged from O.OT i^M to 3.55|iM with a maximal difference of 50.7-fold suggested 
(Table 3.1). The differing response to DX treatment that ranged from sensitive to 
resistance may be indicative of the underlying genetic changes that might have 
conferred such variations. 
4.2. Aneuploidy and DX resistance 
Aneuploidy is considered as the primary cause of genomic instability in neoplastic 
and preneoplastic cells. Aneuploidy destabilizes the karyotype independent of 
mutation, because it corrupts proteins that segregate, synthesize and repair 
chromosomes. Likewise it destabilizes genes. There is wide agreement that recurrent 
genomic aberrations contain genes that are important for tumor development. 
Aneuploidy also allows the tumor cells to achieve a resistant phenotype (Nowell et al , 
1976; Duesberg et al., 2000; Duesberg et al , 2001; Rasnick et a l , 2002). However, 
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according to our data, the degree of aneuploidy in HCC cells did not correlate with 
the levels of DX resistance (P>0.05). Instead, frequent chromosome 10 
rearrangements was suggested among the more resistant cell lines (P=0.007). 
Consistent with our finding, a recent publication by Shimizu et al has also highlighted 
the importance of chromosome 10 in the drug resistance phenotype observed in 
human myelomonocytic leukemia cell lines (Shimizu et al., 2002). Because gene 
amplification and consequent overexpression of MDRl or MRPl have been observed 
in a considerable number of drug-resistant cell lines, it is reasonable to expect that 
additional genes important in drug resistance will be identified by assessment of other 
recurrently abnormal regions. Although the aberrations seem to be random in 9 HCC 
cell lines studies, the potential role of chromosome 10 in drug resistance was defined 
to the loss of 10q26 in a previous study by Shimizu et al, where harboring of critical 
drug resistant gene(s) was postulated (Shimizu et al, 2002). 
4.3. The role of known resistance genes on chromosome 10 
With regard to the importance of chromosome 10 indicated in the resistance 
phenotype of HCC, two best-studied MDR targets on chromosome 10 were first 
considered as possible changes in drug resistant cells. One is the DNA repair protein 
MGMT{\Q(\26) (Yarosh et al., 1985; Lindahl et al , 1988; Pegg et al” 1990-1; Pegg et 
al., 1990-2)，which repairs DNA damage by removing alkyl groups from the 06 
position of guanine. In some cells, drug resistance can be mediated by MGMT, and 
depletion of MGMT activity by the modulator 06-benzylguanine (BG) has been 
shown to reverse resistance phenotype (Pawlik et al” 1998; Nagane et al., 1999). 
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Another one is the tumor suppressor PTEN (10q23.3). PTEN acts as a 
phosphatidylinositol phosphatase with a possible role in phosphatidylinositol 3'-
kinase (PI3'K)-mediated signal transduction and also suggested to be associated with 
the cellular localization of MDM2 in regulation of apoptosis (Davies et al , 1998; 
Maehama et al., 1998). A number of previous studies have suggested that down-
regulation of PTEN (10q23.3) expression may play an important role in the 
development of HCC and the expression level of PTEN may be a potential adjuvant 
parameter in forecasting the progress and prognosis of HCC. Recently, its potential 
role in drug resistance has also been suggested in several reports (Tanaka et al , 2000; 
Grunwald et al., 2002; Tanaka et al , 2003; Zhou et al , 2003). First data by Tanaka et 
al demonstrated that PTEN can induce growth suppression and increase sensitivity to 
DX in bladder cancer cells. Further studies indicated that tumors exhibit drug 
resistance associated with expression of phosphorylated Akt might be effectively 
treated with PTEN gene therapy. 
The expression of both MGMT and PTEN in HCC cells were examined by 
quantitative RT-PCR. The mRNA expression levels determined however suggested 
neither MGMT nov PTEN is related to DX resistance. Thus, it is reasonable to expect 
that the additional resistant genes are harbored on chromosome 10. 
4.4. Identification of novel DX resistance genes on chromosome 10 
In this study, positional mapping for differentially expressed genes on chromosome 
10 indicated two candidate genes, CGH-18 (10q22.1) and ECHSl (10q26.2-q26.3) 
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that were consistently down regulated by 9士3.2-fold and 6.8士6.6-fold respectively in 
four most resistant cell lines (HKCI-1, -2, -3, -CI). Although whole chromosome 10 
was investigated, consistent alteration on genes expression was found only on 1 Oq. Of 
interest was that despite the absence of chromosome 10 aberration in HKCI-Cl, a 
similar down regulation of the two candidate genes was detected. The result 
suggested that, in addition to chromosome abnormality, other mechanisms maybe 
also contribute to the inactivation of these candidate resistance genes. 
CGH-18 is also known as activating signal cointegrator 1，complex subunit 1 
(ASCCl), which is a recent identified coactivator of some nuclear receptors (Kim et 
al., 1999). CGI-18 is considered to possess a capacity to modulate the transcriptional 
activity of androgen receptor (AR) and also have a role in testicular functions (Lee et 
al., 2002; Jung et a l , 2002). Although CGI-18 has not been previously indicated in 
the HCC pathogenesis, our present finding suggested a possible role. Nevertheless, 
although a down-regulation of CGI-18 was verified by quantitative RT-PCR, a 
correlation with DX resistance in the cell lines was not suggested (P>0.05). 
In agreement with our finding, deregulations of ECHSl in HCC have been reported 
from several microarray studies (Okabe et al., 2001; Xu et a l , 2001; Kurokawa et al” 
2003). Moreover, LOH study on chromosome lOq in HCC has defined the recurrent 
regional loss to 10q24-26 (Fujiwara et al., 2000). The ECHSl gene is mapped to 
10q26, which may be suggestive of the inactivation of this gene as a candidate tumor 
suppressor within the region. In deed, a role for ECHSl as a negative marker in the 
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development of rodent liver cancer has been suggested (Yokoyama et al., 1992). 
Whilst the potential function of ECHSI in the HCC pathogenesis remained unclear, 
our present study suggested an inverse relationship between its expression and DX 
resistance. Interestingly, the ECHSI gene is exactly located at the resistance candidate 
region identified by Shimizu et al (Shimizu et al., 2002). The ECHSI gene encodes 
the mitochondrial enoyl-CoA hydratase - short chain 1, which is a major enzyme 
involved in the processing of fatty acid oxidation (Minami-Ishii et al., 1 989). It is 
known that DX can induce cellular apoptosis via the inhibition of topoisomerase II, 
although DNA damage resultant from free radical formation (mostly hydroxyl radical 
OH.) may represent another major mechanism underlying the cytotoxic effect of DX 
(Skladanowski et al., 1994-1; 1994-2; Zeman et al , 1998). DXcan form adducts with 
DNA, and the activity of NADH dehydrogenase in the presence of NADH can 
activate DX to its corresponding semi-quinone and the formation of OH". The fatty 
acid oxidation by ECHSI can augment the development of NADH. Thus, in a 
situation where ECHSI expression is repressed, it is possible that a decrease NADH 
formation may confer a reduced DX effect by the suppression of free radical 
formation and hence DNA damage. 
Another possible explanation for the inverse relationship between ECHSI expression 
and IC50s may be the changes on cell redox status or response to oxidative stress. A 
number of MDR cells have been shown to be more resistant to lipid peroxidation than 
their parental lines (Benchekroun et al., 1990; Hill et al , 1995; Mazzanti et al., 1995; 
Kuhl et al., 1997). Further studies indicated that an increased expression of 
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antioxidant enzymes such as glutathione peroxidase has been attributed to the 
resistance phenotype (Benchekroun et al. 1990, Mazzanti et al. 1995). A high catalase 
activity of these enzymes has also been detected in these resistant cells (Trindade et al. 
1999). Similarly, it is possible that a repressed key lipid peroxidation enzyme, ECHSl, 
can contribute to resistance to oxidative stress induced by DX in HCC cells. 
4.5 Common drug resistance genes 
In case of HCC, few studies have attempted correlation of common drug resistance 
genes with the drug resistance phenotype. However, controversial results were 
suggested from these studies (Table 4.1). Hence, in addition to novel resistance 
candidate genes revealed by utilization of multimodality approaches in this thesis 
(namely SKY, cDNA microarray and quantitative RT-PCR), a number of common 






































































































































































































































































































4.5.1. The roles of classical drug resistance 
The MDRl mediated MDR was the first discovered classic MDR phenotype (Juliano, 
et al. 1976; Chen et al , 1986) and probably still the most widely observed mechanism 
(Gottesman et al , 2002; Chiou et al , 2003; Raspollini et al , 2003.). MDRl is 
expressed in many normal organs and tissues such as the liver, intestine, kidney, 
pancreas, blood-brain barrier and blood-testicular barrier (Hegmann et al , 1992; 
Schinkel et al., 1994). This implies that in tumours arising from these tissues, drug 
resistance is intrinsic (Bradley et al” 1992; Itsubo et al., 1994). While a number of 
studies have suggested an important role of MDRl in drug resistance, in the present 
study no significant correlation between the over-expression of MDR J gene and DX 
resistance was observed (p>0.05). In line with the present study, disappointing results 
have been documented for MDRl modulators in several clinical studies, which in turn 
suggested that MDR] up-regulation is not the sole continuing factor in MDR 
phenotype. 
MRP I is another important ABC transporter that has been indicated to participate in 
the MDR of tumors both in vitro and in vivo (Wang et al., 2000; Hatanaka et al , 
2001). Several studies have demonstrated that MRP, rather than MDR�, has an 
important role in the intrinsic HCC resistance (Nies et al” 2001; Ros et a 1., 2003; 
Wang et al., 2003), a similar correlation between MRPl and increasing DX resistance 
was therefore performed in the present study. Correlation of MRPl gene expression 
in each cell line with the corresponding IC50 values determined, however, did not 
suggest significant association (P>0.05). 
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Based on our present finding, it seems that the classical drug resistance is not a 
critical factor contributing to the intrinsic DX resistance in HCC cells. In order to 
assess the effects of DX on a panel of human tumor cell lines originally derived from 
untreated patients, Gariboldi et al tried to establish a correlation between intrinsic cell 
response and a number of parameters, including intracellular signal transducers 
PKCalpha and drug efflux. Consistent with our findings, 'classic' multispecific drug 
transporters {MDRl and MRP) only seemed to play a minor role in the intrinsic 
resistance to DX in human cancer cells (Gariboldi et al., 2003). The study from 
Gariboldi and ours thus suggested that other factors are involved in the intrinsic DX 
resistance behavior. 
4.5.2. Inhibition of apoptosis and deregulation of cell cycle 
Many chemotherapeutic agents can kill susceptible cells through the apoptosis 
pathway or by targeting the specific growth-deregulating cycles. This finding 
provides new molecular insight into the chemo-resistance mechanisms and suggests 
that apoptosis and/or cell cycle deregulation of cancer cells should be investigated to 
better clarify the mechanisms of cancer chemo-resistance. 
The susceptibility of tumors cells to apoptosis is influenced by a series of different 
proto-oncogenes and tumor suppressor genes. The role of two genes, BCL2 and TP53, 
involved in the chemo-resistance of haematological and solid malignancies, is 
beginning to be better elucidated. In a variety of tumors, inactivated TP53 almost 
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completely suppressed the induction of apoptosis or delayed it extremely. TP53 
deletion has thus been implicated in MDR (Grunicke et al., 1998，Chan et al., 2004). 
Also, there is an increasing amount of evidence showing that an over-expression of 
BCL2 or BCL-XL gene is associated with MDR (Jendrossek et al., 1998; Kuhl et al., 
1997; Miyake et al., 1998). Given the roles of BCL2 and TP53 in apoptosis and drug 
resistance, the effect of their expressions on the response to DX was investigated in 
this thesis. 
Unfortunately, no correlation between the relative expression of BCL2 determined 
and DX resistance was observed (P>0.05). Since many publications have suggested 
that the ratio of BCL2 and other anti-apoptotic genes of the BCL2 family, e.g., BCL-
XL, to the pro-apoptotic BAX is decisive for apoptosis sensitivity of cytotoxic agents, 
the correlation between the ratio of BCL2 to BAXdmd IC50 values were examined, no 
significant correlation was suggested either (P>0.05). A possible explanation for the 
negative result found would be that BAX could activate the process of apoptosis 
independently of BCL2 by directly mediating the activation of mitochondrial 
cytochrome c release. This results in the release of cytochrome c from the 
mitochondria into the cytosol, thereby activating the mitochondrial apoptosis through 
the caspase cascade (Jurgensmeier et al., 1998). Indeed, a significant inverse 
relationship between BAX and IC50 values (p=0.002) was found in this study. 
Therefore, it is possible that BCL2 did not contribute directly to the resistance in our 
series, although a reduced BAX may independently support an anti-apoptotic effect 
and thus a drug resistance phenotype. 
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The expression levels of TP53 were not found to be significantly related to the DX 
resistance (p>0.05). The TP53 gene product is a transcriptional regulator and 
transactivator of a growing number of specific genes implicated in regulation of the 
cell cycle and apoptosis (Daniel et al, 2000; Kannan et al , 2001). P21 is known as a 
principal mediator of TP53 function, since genetic changes in TP53 may lead to loss 
of P21 expression and function. This in turn leads to deregulated cell growth, and is 
thought to contribute to drug resistance behavior of some tumors. The analysis ofP27 
has also been attempted in this thesis. 
The result indicated that, in contrast to TP53 itself, the expression levels of P21 have 
a significant reverse association with DX resistance in HCC cells (P=0.034). If P21 
can reflect TP53 functional status, it might implicate that it was the TP53 activity, but 
not the gene's expression 1 evels that would confer to resistant phenotype of HCC. 
However, inactivation of TP53 by mutation does not necessarily result in loss of P21 
expression since additional factors appear to be involved in the regulation of P21 
(Ding et al., 2001; Sato et al., 2002). Some researchers have proposed that \iP21 is 
positively expressed despite alterations of TP53’ then cell cycle maintained by P2I 
could render tumors less prone to the development drug resistance (Stein et al., 1998; 
Zheng et al., 2004). Hence, in the absence of P21 maintenance, it is possible that drug 
resistance may develop via the escape of cellular senescence. 
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Besides i ts ability on cell cycle regulation, P21 may possess pro-apoptotic ability. 
Although the ability is dependent on the specific cellular content and is different with 
stimulus, it might be another possible explanation for the involvement of P21 
deregulation to the DX resistance. Indeed, a recent study indicated that ectopic P21 
expression can sensitize human cancer to retinoid treatment through the apoptotic 
pathway (Teraishi et al., 2003). A pro-apoptotic effect of P21 was also observed in 
anaplastic thyroid cancer cells treated with manumycin or paclitaxel. The findings 
further suggested that P21 might be required to maintain cell sensitivity to the 
cytotoxic effects of both agents (Yang et al., 2003). 
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In this study, by examining karyotypic and molecular abnormalities in 9 HCC cell 
lines with differing resistance to doxorubicin, several significant findings in the 
doxorubicin chemo-resistance of HCC were found. However, due to the limited 
number of HCC cell lines examined, the significance of these identified candidates 
need to be examined on a large series of HCC specimen. In addition, according to 
SKY data only the aberrations on chromosome 10 were analyzed. It is possible that 
genes harboring on other arms are also involved in drug resistance mechanism. Due 
to these limitations of current study, some future studies have suggested in the 
following parts. 
5.1. Validate significant in vitro findings by clinical trials 
Drug resistance remains a major challenge in the treatment of HCC and other human 
cancers. So far, there has been no single therapeutic modality that is able to 
sufficiently and effectively reverse drug resistance clinically. One of the major 
obstacles is the presence of multiple drug resistance mechanisms that has 
compromised the efficacy of anticancer therapies. However, it appears likely that 
these diverse resistant mechanisms will ultimately be merged into only a few basic 
cellular mechanisms by which cell death or survival is governed in the individual cell. 
In this thesis, a key enzyme in fatty acid oxidation, ECHSl, was found to be related to 
DX resistance in HCC cell lines for the first time. The apoptotic molecule BAX and 
cell cycle regulator P21 were also observed to be significantly related to the IC50 
values determined in cell lines examined. The spectrum of these molecular 
aberrations suggests a model for DX resistance of HCC cells through apoptosis, cell 
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cycle regulation and oxidation pathways, all of which may hold value in improving 
the design of more rational therapeutic agents in future. 
However, the significance of these identified drug resistance genes in clinical 
response must be examined prior to any clinical application. Within our hospital, a 
clinical trail on drug response to DX and other common chemotherapeutic agents has 
just been completed. Biopsies on a total of 183 HCC cases with complete 
documentations on chemotherapeutic response are hence available. It is therefore 
possible to employ the immunohistochemical technique to detect the expression 
levels of ECHSl as well as BAX and P21. The association of these proteins with the 
drug response can thus be evaluated. The results obtained will further enable an 
evaluation of these candidate genes in the chemotherapeutic response of HCC 
patients. 
5.2. Molecular mechanisms in inactivation of ECHSl in resistant cells 
Attempts can be made to investigate the molecular mechanisms underlying the 
inactivation of the novel resistant gene ECHSl in the drug resistant cells. (1) ECHSl 
is located at 10q26, a recurrent loss region in HCC (Fujiwara et al., 2000). Therefore, 
loss of heterozygosity (LOH) might contribute to the down-regulation of ECHSl 
expression to some extend. (2) Mutation is another important way to inactivate 
potential tumor suppressor genes in cancer cells. Combined "exon by exon" PGR 
mediated single strand conformational polymorphism analysis (SSCP) analysis, 
followed by direct DNA sequencing can be used to screen ECHSl gene mutation 
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status in HCC cells. (3) Aberrant DNA methylation of the promoter region is a key 
mechanism for inactivation of genes by preventing the binding of transcription factors 
to the promoter. The function of ECHSl may also be blocked by methylation of its 
promoter. 
Furthermore, in order to understand the downstream events of ECHSl expression, 
expression clone constructed that contains the ECHSl gene can be transfected into the 
resistant cells. Its effect on the DX resistance phenotype can be assessed by MTT. The 
changes of gene expression patterns can be determined by cDNA microarray. Some 
clues on the related downstream events might be identified. Continued efforts are also 
needed, especially in designing pre-clinical studies of animal models. Obviously, 
identification of the mechanisms of action of ECHSl may bring new hope for HCC 
therapy and lead to further understanding of the mechanisms of HCC resistance and 
may be identified as a novel target for therapy. 
5.3 Further utilization of cDNA microarray data 
cDNA microarray provides a great number of data on the genes expression. In this 
thesis, only those in chromosome 10 are analyzed since the importance of 
chromosome 10 has been indicated from SKY. Nevertheless, it is also possible for 
drug resistant genes to be harboring on other chromosome regions. Intrinsic pattern of 
gene expression changes between the different cell lines with differing resistance 
phenotypes could also be suggested from cDNA microarray data. In an attempt to 
further maximize the identification of pattern of genes expression changes in 
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association with DX resistance, bioinformatics analysis by such methods as 
Significance Analysis of Microarrays (SAM) and Prediction Analysis for Microarrays 
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